EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review

Aleksandra Złotowska iD, Julia Kacer iD, Zuzanna Dybko, Mateusz Dudek iD, Wiesława Duszyńska iD

Journal of Clinical Medicine · 17.07.2026 · 15 (14) · 5617

DOI: 10.3390/jcm15145617 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.07.2026. Verfasst von Aleksandra Złotowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Student Scientific Association at the Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University…. Die Arbeit nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The alarming increase in the number of new bacterial defense mechanisms is exacerbating the problem of antibiotic resistance and poses a serious obstacle to the treatment of bacterial infections. Despite the approval of numerous new antibiotics by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), mainly from the beta-lactam group since 2000, only some of them possess unique mechanisms of action and activity against multidrug-resistant Gram-negative bacilli (MDR GNB), including carbapenem resistance. Eravacycline (EVT), formerly known as TP-434, is a newly developed non-beta-lactam, fully synthetic tetracycline derivative, approved for the treatment of complicated intra-abdominal infections (cIAIs) in adults.

Results

The analysis demonstrated significant efficacy of EVT across a wide range of in vitro and in vivo studies against MDR GNB, including carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE) and Gram-positive vancomycine-resistant pathogens.

Conclusions

The broad spectrum of activity and favorable safety profile of EVT are well-documented in the treatment of critically ill patients. However, its efficacy against clinically relevant Gram-negative bacteria varies depending on specific species and resistance phenotypes, particularly among carbapenem-resistant and extensively drug-resistant (XDR) isolates.

Schlagwörter

Stichwörter der Autor:innen

Gram-negative bacteriaMDRantimicrobial resistanceeravacyclineβ-lactam antibiotics

Autor:innen und Institutionen

  • Student Scientific Association at the Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland.
  • Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland.

ORCID-Profile: Aleksandra Złotowska, Julia Kacer, Mateusz Dudek, Wiesława Duszyńska

Zitieren

APA

Złotowska, A., Kacer, J., Dybko, Z., Dudek, M., & Duszyńska, W. (2026). Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review. Journal of Clinical Medicine, 15(14), 5617. https://doi.org/10.3390/jcm15145617

Vancouver

Złotowska A, Kacer J, Dybko Z, Dudek M, Duszyńska W. Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review. Journal of Clinical Medicine. 2026;15(14):5617. doi:10.3390/jcm15145617

BibTeX
@article{Zotowska2026,
  author = {Złotowska, Aleksandra and Kacer, Julia and Dybko, Zuzanna and Dudek, Mateusz and Duszyńska, Wiesława},
  title = {Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {5617},
  doi = {10.3390/jcm15145617}
}
Kostenlos starten →